RT Journal Article
SR Electronic
T1 Validation testing to determine the effectiveness of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20237784
DO 10.1101/2020.12.01.20237784
A1 Ferguson, Jack
A1 Dunn, Steven
A1 Best, Angus
A1 Mirza, Jeremy
A1 Percival, Benita
A1 Mayhew, Megan
A1 Megram, Oliver
A1 Ashford, Fiona
A1 White, Thomas
A1 Moles-Garcia, Emma
A1 Crawford, Liam
A1 Plant, Tim
A1 Bosworth, Andrew
A1 Kidd, Michael
A1 Richter, Alex
A1 Deeks, Jonathan
A1 McNally, Alan
YR 2020
UL http://medrxiv.org/content/early/2020/12/24/2020.12.01.20237784.abstract
AB Lateral flow devices are quickly being implemented for use in large scale population surveillance programs for SARS-CoV-2 infection in the United Kingdom. These programs have been piloted in city wide screening in the city of Liverpool, and are now being rolled out to support care home visits and the return home of University students for the Christmas break. Here we present data on the performance of Lateral Flow devices to test almost 8,000 students at the University of Birmingham between December 2nd and December 9th 2020. The performance is validated against almost 800 samples using PCR performed in the University Pillar 2 testing lab, and theoretically validated on thousands of Pillar 2 PCR testing results performed on low-prevalence care home testing samples. Our data shows that Lateral Flow Devices do not detect infections presenting with PCR Ct values over 29-30, meaning that only 3.2% (95% CI 0.6% to 15.6%) of total cases in the student population were detected, but that as many of 85% of cases tested in the Pillar 2 PCR lab would have been detected theoreticallyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe testing work in this project is funded by the UK Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of sample result data, and of anonymised waste samples from student testing programs in this study was reviewed by the Ethics review committee of the College of Medical and Dental Sciences at the University of Birmingham. A waiver was granted allowing samples to be used under ethics gained to aid assay development (NRES Committee West Midlands - South Birmingham 2002/201 Amendment Number 4, 24 April 2013)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the supplementary file